Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloVax vs Chemotherapy in R/M SCCHN
NCT02624999Phase 2Withdrawn
- Sponsor
- Mirror Biologics, Inc.
- Start
- Dec 2016
- Primary completion
- Dec 2016
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AlloVax in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Mirror Biologics, Inc. Primary endpoints: Safety and tolerability at 119 days and Overall Survival at 119 days. Planned start Dec 2016; status: withdrawn.
02
Drugs
AlloVax
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02624999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624999.